This content is machine translated Multiple sclerosis Therapy, pathogenesis and clinic of the heterogeneous disease in view The world’s largest congress dedicated to research on the pathogenesis, diagnosis and treatment of multiple sclerosis and related neurological disorders, ECTRIMS, once again brought together renowned experts in MS research,…
View Post 4 min This content is machine translated Multiple sclerosis Mastering challenges in everyday practice The therapeutic landscape for multiple sclerosis is now broad. Nevertheless, the goal of neuroprotective and remyelinating therapy has not yet been achieved. The aim of the 37th Congress of the…
View Post 4 min This content is machine translated ECTRIMS Congress in Berlin International MS experts provided an update on research and therapy How can Big Data be used in the field of multiple sclerosis? And what’s the latest on existing treatment options? The ECTRIMS congress in Berlin clarified.
View Post 5 min This content is machine translated ECTRIMS Hot Topic Session The role of autologous hematopoietic stem cell transplantation in MS. In recent years, impressive results have been published on autologous hematopoietic stem cell transplantation in patients with multiple sclerosis. In a pro-con debate at the 32nd Congress of the European…
View Post 6 min This content is machine translated Highlights from the ECTRIMS Congress 2013 New therapeutic approaches and an exciting hypothesis on the pathogenesis From October 2-5, 2013, the 29th ECTRIMS (Congress of the European Committee for Research and Treatment in Multiple Sclerosis) and the 18th RIMS (Annual Conference of Rehabilitation in MS) were…
View Post 3 min This content is machine translated Approval Teriflunomide (Aubagio®) Significantly lower risk of disability progression The more a patient with MS is limited in different areas of life by his increasing disability, the worse his health status becomes. In Switzerland, an oral MS treatment, teriflunomide,…
